China pricing authority issues first significant antitrust fines
Tuesday, 22 November 2011
Rosalind Donald
China’s National Development and Reform Commission (NDRC) has imposed fines of almost 7 million renminbi (around €813,000) on two pharmaceutical companies for abuse of dominance in the market for blood pressure drugs. The fines are the first significant penalties the authority has issued for breach of competition law.
Subscription required to view this article
This content can only be accessed by GCR subscribers.
A subscription includes 10 issues of the journal, 2 signature surveys - The GCR100 and Rating Enforcement, 10 GCR special reports and full access to current print and online content.
Please note: If you would like online access to all archived content, you will need a Premium subscription.
If you are a GCR subscriber, please login to access this content:
Comments
You must Subscribe or Log In to make comments.
Comment Terms & Conditions
Back to top